Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Review and Preview01:10

Review and Preview

8.4K
In statistics, several tools are used to interpret the data. Measures of central tendency represent the characteristics of the data, such as mean, median, and mode. Additionally, measures of variance like standard deviation and range are used to find the spread of data from the mean. Relative standing measures the distance between data locations. Commonly used measures of relative standings are percentile, z score, and quartiles.
Percentiles are a type of fractile that partition data into...
8.4K
Review and Preview01:13

Review and Preview

11.5K
Data are individual items of information obtained from a population or sample. Data may be classified as qualitative (categorical), quantitative continuous, or quantitative discrete. Because it is not practical to measure the entire population in a study, researchers use samples to represent the population. A random sample is a representative group from the population chosen by using a method that gives each individual in the population an equal chance of being included in the sample. Random...
11.5K
Ethics in Research01:56

Ethics in Research

25.7K
Today, scientists agree that good research is ethical in nature and is guided by a basic respect for human dignity and safety. However, this has not always been the case. Modern researchers must demonstrate that the research they perform is ethically sound.
25.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Upfront management of brain metastases in oncogene‑addicted NSCLC - An EORTC survey.

Lung cancer (Amsterdam, Netherlands)·2026
Same author

A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib: Results from the RET-MAP Registry.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Targeting MET in EGFR-Mutated NSCLC.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

Improving transthyretin cardiac amyloidosis detection from electrocardiograms through the Willem artificial intelligence platform.

Heart rhythm·2026
Same author

The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a Sub-analysis of the APHINITY trial.

Journal of the National Cancer Institute·2026

Related Experiment Video

Updated: Feb 6, 2026

Comprehensive Understanding of Inactivity-Induced Gait Alteration in Rodents
04:37

Comprehensive Understanding of Inactivity-Induced Gait Alteration in Rodents

Published on: July 6, 2022

2.9K

Mammaprint™: a comprehensive review.

Mariana Brandão1, Noam Pondé1, Martine Piccart-Gebhart1

  • 1Institut Jules Bordet & L'Université Libre de Bruxelles (U.L.B.), 121, 1000, Brussels, Belgium.

Future Oncology (London, England)
|August 30, 2018
PubMed
Summary

MammaPrint, a 70-gene breast cancer test, helps identify early-stage patients who can avoid chemotherapy. While its prognostic value is proven, its predictive and clinical utility requires further investigation for personalized treatment.

Keywords:
adjuvant chemotherapybreast neoplasmsgene-expression signatures

More Related Videos

Comprehensive Endovascular and Open Surgical Management of Cerebral Arteriovenous Malformations
14:58

Comprehensive Endovascular and Open Surgical Management of Cerebral Arteriovenous Malformations

Published on: October 20, 2017

10.3K
Chromatographic Fingerprinting by Template Matching for Data Collected by Comprehensive Two-Dimensional Gas Chromatography
10:14

Chromatographic Fingerprinting by Template Matching for Data Collected by Comprehensive Two-Dimensional Gas Chromatography

Published on: September 2, 2020

5.5K

Related Experiment Videos

Last Updated: Feb 6, 2026

Comprehensive Understanding of Inactivity-Induced Gait Alteration in Rodents
04:37

Comprehensive Understanding of Inactivity-Induced Gait Alteration in Rodents

Published on: July 6, 2022

2.9K
Comprehensive Endovascular and Open Surgical Management of Cerebral Arteriovenous Malformations
14:58

Comprehensive Endovascular and Open Surgical Management of Cerebral Arteriovenous Malformations

Published on: October 20, 2017

10.3K
Chromatographic Fingerprinting by Template Matching for Data Collected by Comprehensive Two-Dimensional Gas Chromatography
10:14

Chromatographic Fingerprinting by Template Matching for Data Collected by Comprehensive Two-Dimensional Gas Chromatography

Published on: September 2, 2020

5.5K

Area of Science:

  • Oncology
  • Genomics
  • Biomarker Discovery

Background:

  • Breast cancer (BC) incidence is rising globally, with most cases diagnosed early.
  • MammaPrint is a 70-gene expression signature for early BC prognosis.
  • Its role in predicting treatment response and clinical utility is debated.

Purpose of the Study:

  • To review MammaPrint's mechanism, clinical application, and limitations.
  • To summarize cost-effectiveness studies.
  • To offer a future perspective on MammaPrint for personalized early BC treatment.

Main Methods:

  • Review of existing literature on MammaPrint.
  • Analysis of prognostic and predictive validation studies.
  • Examination of clinical utility and cost-effectiveness data.

Main Results:

  • MammaPrint's prognostic capability in early breast cancer is well-validated.
  • Its predictive value for adjuvant chemotherapy benefit remains controversial.
  • Clinical utility and cost-effectiveness data are being evaluated.

Conclusions:

  • MammaPrint is a validated prognostic biomarker for early breast cancer.
  • Further research is needed to clarify its predictive and clinical utility.
  • It holds promise for personalizing treatment strategies in early BC.